MENU
+Compare
NRIX
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$19.31
Change
-$0.05 (-0.26%)
Capitalization
1.96B

NRIX Nurix Therapeutics Forecast, Technical & Fundamental Analysis

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders... Show more

NRIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NRIX with price predictions
Dec 24, 2025

NRIX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for NRIX moved above the 200-day moving average on December 01, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where NRIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 154 cases where NRIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NRIX moved out of overbought territory on December 09, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NRIX turned negative on December 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NRIX broke above its upper Bollinger Band on December 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.271) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (19.084) is also within normal values, averaging (311.015).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NRIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NRIX is expected to report earnings to fall 10.23% to -92 cents per share on February 18

Nurix Therapeutics NRIX Stock Earnings Reports
Q4'25
Est.
$-0.92
Q3'25
Missed
by $0.20
Q2'25
Beat
by $0.19
Q1'25
Beat
by $0.09
Q4'24
Missed
by $0.07
The last earnings report on October 09 showed earnings per share of -102 cents, missing the estimate of -82 cents. With 271.04K shares outstanding, the current market capitalization sits at 1.96B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1700 Owens Street
Phone
+1 415 660-5320
Employees
284
Web
http://www.nurixtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMUJX24.770.10
+0.41%
MFS Utilities R4
SNTFX20.330.03
+0.15%
Steward Values Enhanced International R6
GEMRX16.250.02
+0.12%
abrdn Emerging Markets R
GMAGX13.530.01
+0.07%
Invesco Advantage International R5
OAZIX32.270.02
+0.06%
Oakmark International R6

NRIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with KYMR. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
+0.36%
KYMR - NRIX
65%
Loosely correlated
-0.48%
KURA - NRIX
55%
Loosely correlated
+2.50%
XNCR - NRIX
55%
Loosely correlated
-0.13%
SYRE - NRIX
54%
Loosely correlated
-0.54%
OCUL - NRIX
53%
Loosely correlated
-0.24%
More

Groups containing NRIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
+0.36%
NRIX
(2 stocks)
76%
Closely correlated
-1.22%